Aclaris Therapeutics Inc 2025年度报告

Securities registered pursuant to Section12(b) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule405 of the Securities Act. Yes◻No⌧ Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to suchfiling requirements for the past 90days.Yes⌧No◻ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submit suchfiles).Yes⌧No◻ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company oremerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company”in Rule 12b-2 of the Exchange Act. Large accelerated filer◻Accelerated filer◻Non-accelerated filer⌧Smaller reporting company⌧Emerging growth company◻ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.◻ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm thatprepared or issued its audit report.◻ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included inthe filing reflect the correction of an error to previously issued financial statements.◻ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensationreceived by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).◻ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes◻No⌧ As of June 30, 2025, the last business day of the registrant’s last completed second quarter, the aggregate market value of the registrant’s commonstock held by non-affiliates of the registrant was approximately $149.2 million based on the closing price of the registrant’s common stock, as reported bythe Nasdaq Global Select Market, on such date. As of January 30, 2026, 120,595,189shares of common stock, $0.00001 par value, were outstanding. DOCUMENTS INCORPORATED BY REFERENCE None. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (this “Annual Report”) contains forward-looking statementswithin the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), andSection21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that involvesubstantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item1. “Business,” Part I, Item 1A. “Risk Factors,” and Part II, Item7. “Management’s Discussion andAnalysis of Financial Condition and Results of Operations,” but are also contained elsewhere in thisAnnual Report. In some cases, you can identify forward-looking statements by the words “may,” “might,”“can,” “will,” “to be,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,”“believe,” “estimate,” “predict,” “project,” “potential,” “likely,” “continue” and “ongoing,” or the negativeof these terms, or other comparable terminology intended to identify statements about the future. Thesestatements involve known and unknown risks, uncertainties and other factors that may cause our actualresults, levels of activity, performance or achievements to be materially different from the informationexpressed or implied by these forward-looking statements. Although we believe that we have a reasonablebasis for each forward-looking statement contained in this Annual Report, we caution you that thesestatements are based on a combination of facts and factors currently known by us and our expectations ofthe future, about which we cannot be certain. Forward-looking statements include statements about: ●our plans to develop our product candidates;●the timing of our planned clinical trials of our product candidates and the reporting of the resultsfrom these trials;●the clinical utility of our product candidates and our expectations about their properties andtherapeutic effects;●our plans and expectations rela